Heart failure & cardiomyopathiesCohort study
Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors
- single-centre retrospective cohort
Authors' conclusion
Patients requiring exercise echocardiography to document treatment-qualifying LVOTO do not exhibit a milder disease phenotype and derive similar treatment benefits from mavacamten compared to those with resting or Valsalva-provoked obstruction. Exercise echocardiography identifies a substantial proportion of symptomatic HCM patients with significant LVOTO missed by resting assessment and is essential for guiding treatment eligibility.
Study context
- Population
- Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients treated with mavacamtensymptomatic oHCM patients treated with mavacamten
- Participants
- 56 patients
- Exposure
- exercise vs non-exercise
Main finding
As reported in the abstract
Proportion qualifying exclusively during exercise echocardiography
42.9%
Observational data: associations, not effects.
Further findings
Baseline exercise capacity (pVO2) · similar baseline functional limitation
Non-obstructive gradients (<30 mmHg) · 24 weeks
NYHA class improvement · 24 weeks · without significant between-group differences
- Baseline exercise capacity (pVO2): P = .550
- Non-obstructive gradients (<30 mmHg): P = .646
- NYHA class improvement: P = .266
Original publication
Summarised from the published abstract; every number is checked against it